Simulations Plus (NASDAQ:SLP) Downgraded to “Sell” Rating by StockNews.com

StockNews.com cut shares of Simulations Plus (NASDAQ:SLP) from a hold rating to a sell rating in a report released on Monday.

Other equities research analysts also recently issued research reports about the stock. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Thursday, October 24th. KeyCorp started coverage on Simulations Plus in a report on Monday, July 29th. They set an “overweight” rating and a $47.00 target price for the company. BTIG Research cut their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Finally, JMP Securities initiated coverage on Simulations Plus in a research note on Tuesday, July 16th. They set a “market perform” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.50.

Simulations Plus Trading Up 7.8 %

Shares of SLP opened at $30.82 on Monday. Simulations Plus has a 52 week low of $27.22 and a 52 week high of $51.22. The firm has a market cap of $618.56 million, a price-to-earnings ratio of 62.90 and a beta of 0.71. The stock has a 50 day moving average of $31.82 and a 200-day moving average of $39.60.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $19.73 million. During the same period last year, the business posted $0.18 earnings per share. The firm’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, sell-side analysts predict that Simulations Plus will post 1.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $31.26, for a total transaction of $625,200.00. Following the sale, the director now owns 3,481,592 shares of the company’s stock, valued at $108,834,565.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 60,750 shares of company stock valued at $1,905,655 in the last three months. 20.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Simulations Plus

A number of hedge funds and other institutional investors have recently made changes to their positions in SLP. nVerses Capital LLC boosted its holdings in shares of Simulations Plus by 1,100.0% in the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after acquiring an additional 1,100 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Simulations Plus during the 1st quarter valued at $57,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Simulations Plus in the 1st quarter worth $70,000. Los Angeles Capital Management LLC acquired a new stake in shares of Simulations Plus in the second quarter valued at $206,000. Finally, Arizona State Retirement System bought a new position in Simulations Plus during the second quarter valued at about $218,000. 78.08% of the stock is currently owned by institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.